GFY

SOF Week 2024: Immersive Wisdom awarded DoD-wide Five-Year sole-source $25MM ordering contract through GFY 2029 by the U.S. Air Force for groundbreaking TRL-9 No-Bandwidth and Low-Bandwidth Communications Software

Retrieved on: 
Monday, May 6, 2024
Air force, Army, Intermittency, GFY, Navy, USAF, IDIQ, Space force, Mobile phone

TAMPA, Fla., May 5, 2024 /PRNewswire/ -- Immersive Wisdom, Inc., provider of a proven TRL-9 distributed communications and ops center software platform for Denied, Degraded, Intermittent, and Limited-Bandwidth (DDIL) environments announced at SOF Week 2024 that it has been awarded a DoD-wide five-year sole-source $25MM ceiling IDIQ ordering contract by the USAF for its No-Bandwidth and Low-Bandwidth communications software.

Key Points: 
  • Immersive Wisdom awarded DoD-wide Five-Year sole-source $25MM ordering contract through GFY 2029 by the U.S. Air Force
    The sole-source contract allows SOF, Army, Air Force, Space Force, Navy, and Marines to rapidly buy and install ready-now Immersive Wisdom software to support disaggregated communications in contested environments.
  • "This five-year ordering contract puts Immersive Wisdom's low-bandwidth and no-bandwidth communications software into the hands of the warfighter immediately, and keeps it there."
  • said Michael Appelbaum, CEO of Immersive Wisdom.
  • "In literally weeks, end users can be operating with capabilities that they need critically for contested environments."

BVI Launches PODEYE Hydrophobic Monofocal IOL in Japan

Retrieved on: 
Thursday, April 18, 2024
Surgeon, GFY, Lens, POD, Intraocular lens, Health, PMDA, Ophthalmology, Pharmaceutical industry

WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) --  BVI, the most dynamic, diversified company in ophthalmology, announced today the official launch of the PODEYE hydrophobic monofocal IOL in Japan following approval by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). The achievement represents another significant step in BVI’s plan to launch its range of IOLs in Japan over the near-term.

Key Points: 
  • BVI continues to execute its roadmap of IOL launches in Japan, the world's third-largest IOL-valued market1
    The PODEYE hydrophobic monofocal is perfectly suited to the Japanese market, where hydrophobic IOLs constitute almost 96% of the total monofocal IOL units in Japan1
    Following the 2023 launch of FINEVISION HP Hydrophobic Trifocal IOL, PODEYE becomes the second BVI IOL to be available in Japan
    WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) --  BVI, the most dynamic, diversified company in ophthalmology, announced today the official launch of the PODEYE hydrophobic monofocal IOL in Japan following approval by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
  • Anticipate more groundbreaking product launches from us in Japan and many other major markets globally.” said Shervin Korangy, President and CEO of BVI.
  • Given that Japan is primarily a hydrophobic market, surgeons in Japan, like their counterparts worldwide, will appreciate the proprietary, hydrophobic ‘GFY®’ material from which BVI IOLS are made providing 100% glistening-free material.
  • Alongside its patented GFY material featured exclusively in BVI lenses, BVI also develops and supplies approximately 20% of IOL material for competing IOL companies globally from its facility in Florida, US.